Skip to main content
. 2023 Jan 30;7:e2200540. doi: 10.1200/PO.22.00540

FIG 1.

FIG 1.

(A) PFS by STK11 mutational status, (B) OS by EGFR mutational status, (C) OS by EGFR mutational status among patients receiving comprehensive LCT, and (D) OS of patients without EGFR mutations, with EGFR mutations without receipt of EGFR-targeted therapy, and with EGFR mutations with receipt of EGFR-targeted therapy. LCT, local consolidative therapy; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.